BioSpace News Archive

$13 Million Bill & Melinda Gates Foundation Grant to Fund Development Program to Address Lack of Family Planning Options Globally

EY announces the launch of Pointellis, a new solution that supports the provision of individualized therapies that target each cancer patient’s specific treatment needs.

IDTechEx, expert providers of market intelligence in emerging technologies, have forecast the medical wearables market to be worth $19.7 billion by the year 2024 in their latest research.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, announced that it will report its second quarter 2019 financial results on Thursday, August 8, 2019.

Dr. Reddy’s Laboratories Ltd. announced the launch of Pregabalin Capsules a therapeutic equivalent generic version of Lyrica® (pregabalin) Capsules approved by the U.S. Food and Drug Administration (USFDA).

Verzenio is the first and only CDK4 & 6 inhibitor in combination with fulvestrant to achieve statistically significant improvement in overall survival

Northwestern Medicine Hospitals ranked among America’s “Best Hospitals” by U.S. News & World Report [30-July-2019] CHICAGO , July 30, 2019 /PRNewswire/ -- U.S. News & World Report has recognized four Northwestern Medicine hospitals in its 2019-20 Best Hospitals rankings. Northwestern Memorial Hospital is recognized among the top hospitals in th

WellCare Health Plans, Inc. reported results for the quarter ended June 30, 2019.

SpringWorks Therapeutics, Inc. announced that the European Commission has granted Orphan Drug Designation for mirdametinib, an oral, small molecule inhibitor of MEK1 and MEK2, for the treatment of neurofibromatosis type 1.

XORTX Therapeutics Inc. is pleased to announce that Dr. Allen Davidoff, CEO, will be presenting at VirtualInvestorConferences.com on August 1st, a live, interactive online event where investors are invited to ask the Company questions in real-time – see details below.